Novartis’s chief data and digital officer for biomedical research explains how data platform investments are paying off in AI safety prediction, generative chemistry, and faster translation

Novartis&rsquo;s chief data and digital officer for biomedical research explains how data platform investments are paying off in AI safety prediction, generative chemistry, and faster translation

McKinsey colleagues Alex Devereson and Nav Nagra explore cutting-edge technology trends, tackle pressing industry challenges, and uncover R&D innovations with biopharma leaders. Whether you're a seasoned professional or a curious enthusiast, this series offers valuable insights and thought-provoking discussions that will keep you informed and inspired. Tune in and stay ahead of the curve in the ever-evolving world of biopharma. 

McKinsey colleagues Alex Devereson and Nav Nagra explore cutting-edge technology trends, tackle pressing industry challenges, and uncover R&amp;D innovations with biopharma leaders. Whether you're a seasoned professional or a curious enthusiast, this series offers valuable insights and thought-provoking discussions that will keep you informed and inspired. Tune in and stay ahead of the curve in the ever-evolving world of biopharma.

Eureka!

McKinsey colleagues Alex Devereson and Nav Nagra explore cutting-edge technology trends, tackle pressing industry challenges, and uncover R&D innovations with biopharma leaders. Whether you're a seasoned professional or a curious enthusiast, this series offers valuable insights and thought-provoking discussions that will keep you informed and inspired. Tune in and stay ahead of the curve in the ever-evolving world of biopharma.

McKinsey colleagues Alex Devereson and Nav Nagra explore cutting-edge technology trends, tackle pressing industry challenges, and uncover R&amp;D innovations with biopharma leaders. Whether you're a seasoned professional or a curious enthusiast, this series offers valuable insights and thought-provoking discussions that will keep you informed and inspired. Tune in and stay ahead of the curve in the ever-evolving world of biopharma.

Novartis’s Christian Diehl on scaling AI beyond the demo

Pfizer’s chief medical affairs officer talks about measuring medical affairs’ true impact, leading change at scale, and what patient-first really means.

Pfizer&rsquo;s chief medical affairs officer talks about measuring medical affairs&rsquo; true impact, leading change at scale, and what patient-first really means.

Pfizer’s Alex Condoleon on medical affairs accountability

Bob Li, AstraZeneca's Senior Vice President, Global Head of Medical Affairs, Oncology, on why only seven percent of cancer patients get access to clinical trials, and what decentralized trials, AI, and international collaboration could do to change that within a decade. 

Bob Li, AstraZeneca's Senior Vice President, Global Head of Medical Affairs, Oncology, on why only seven percent of cancer patients get access to clinical trials, and what decentralized trials, AI, and international collaboration could do to change that within a decade.&nbsp;

AstraZeneca's Bob Li on the MARS mission to eliminate cancer

McKinsey partner Fangning Zhang discusses what’s driving China’s acceleration in drug discovery, why intense competition is fueling speed and cost efficiency, and what global R&D leaders need to do to build a genuine China strategy.

McKinsey partner Fangning Zhang discusses what&rsquo;s driving China&rsquo;s acceleration in drug discovery, why intense competition is fueling speed and cost efficiency, and what global R&amp;D leaders need to do to build a genuine China strategy.

Novartis’s Christian Diehl on scaling AI beyond the demo

In 1 playlist(s)

Eureka!

Social links

Follow podcast

Recent clips